The Pancreatic Cancer Diagnostic Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Pancreatic Cancer Diagnostic Market:
https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-diagnostic-global-market-report
According to The Business Research Company’s Pancreatic Cancer Diagnostic Global Market Report 2024, The pancreatic cancer diagnostic market size has grown strongly in recent years. It will grow from $3.92 billion in 2023 to $4.21 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to growing genomic and molecular profiling, chemotherapy developments, radiation therapy refinements, research on pancreatic cancer genetics, awareness campaigns and early detection efforts.
The pancreatic cancer diagnostic market size is expected to see strong growth in the next few years. It will grow to $5.74 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to liquid biopsy advancements, targeted therapies, artificial intelligence in diagnostics, personalized medicine approaches, early detection biomarkers, neoadjuvant therapies. Major trends in the forecast period include immunotherapy research, advancements in imaging technologies, surgical innovations, global collaborative research initiatives, integration of big data analytics.
The rise in the prevalence of pancreatic cancer is expected to propel the growth of the pancreatic cancer diagnostic market going forward. Pancreatic cancer refers to a condition in which the tissues of the pancreas develop malignant (cancer) cells. The rise in pancreatic cancer is mostly driven by smoking, diabetes, chronic pancreatitis, a family history of pancreatic cancer, inflammation of the pancreas, and some genetic disorders. Diagnosis in pancreatic cancer is crucial for guiding treatment decisions, determining the stage of cancer, identifying the specific characteristics of the tumor, and tailoring treatment approaches to improve outcomes and optimize patient care. For instance, in 2023, according to the American Society of Clinical Oncology, a US-based professional organization, in the United States, 64,050 individuals (33,130 men and 30,920 women) are anticipated to be diagnosed with pancreatic cancer in 2023. It is the eighth most frequent cancer in women and the tenth most frequent in men. The frequency of new instances of pancreatic cancer has increased by about 1% per year in both men and women. Therefore, the rise in the prevalence of pancreatic cancer is driving the growth of the pancreatic cancer diagnostic market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=11981&type=smp
The pancreatic cancer diagnostic market covered in this report is segmented –
1) By Product: Instruments, Consumables, Services
2) By Treatment: Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy
3) By Cancer Type: Exocrine, Adenocarcinoma, Squamous Cell Carcinoma, Adenosquamous Carcinoma, Colloid Carcinoma, Endocrine
4) By Test Type: Imaging Test, Biopsy, Blood Test, Genomic Test, Other Test Types
5) By End-User: Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, Other End-Users
Product innovations are a key trend gaining popularity in the pancreatic cancer diagnostic market. Companies operating in the pancreatic cancer diagnostic market are adopting innovative solutions to sustain their position in the market. For instance, in March 2023, Prestige Biopharma Limited, a Singapore-based biopharmaceutical company, launched the first-in-class PAUF-detecting diagnostic kit, a powerful instrument for the early detection of pancreatic cancer. PAUF (Pancreatic Adenocarcinoma Upregulated Factor) is a unique tumor-specific biomarker associated with early metastasis and overexpression in about 80% of pancreatic cancer cases. The innovative diagnostic technique has high sensitivity and specificity for identifying PAUF. Preliminary studies showed that the expression level of PAUF in the blood plasma of pancreatic cancer patients is almost 1.9 times higher than that of healthy individuals, according to Prestige Biopharma’s IDC (Innovative Discovery Center).
The pancreatic cancer diagnostic market report table of contents includes:
1. Executive Summary
2. Pancreatic Cancer Diagnostic Market Characteristics
3. Pancreatic Cancer Diagnostic Market Trends And Strategies
4. Pancreatic Cancer Diagnostic Market – Macro Economic Scenario
5. Global Pancreatic Cancer Diagnostic Market Size and Growth
………………….
31. Pancreatic Cancer Diagnostic Market Other Major And Innovative Companies
32. Global Pancreatic Cancer Diagnostic Market Competitive Benchmarking
33. Global Pancreatic Cancer Diagnostic Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Pancreatic Cancer Diagnostic Market
35. Pancreatic Cancer Diagnostic Market Future Outlook and Potential Analysis
Read Related Topics:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
